We are live on ! Find out more
RNA

Atrium Therapeutics
RNA

162 hedge funds and large institutions have $198M invested in Atrium Therapeutics in 2026 Q1 according to their latest regulatory filings, with 162 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

86.6% more ownership

Funds ownership: 0% → 86.6% (+87%)

94% less call options, than puts

Call options by funds: $968K | Put options by funds: $15.6M

Holders
162
Holders Change
+162
Holders Change %
–
% of All Funds
1.99%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
162
Increased
–
Reduced
–
Closed
–
Calls
$968K
Puts
$15.6M
Net Calls
-$14.6M
Net Calls Change
-$14.6M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$21.8M
2
BlackRock
BlackRock
New York
+$16.9M
3
RCM
RA Capital Management
Massachusetts
+$12.1M
4
TAL
TIG Advisors LLC
New York
+$8.54M
5
PCM
Pentwater Capital Management
Florida
+$8.47M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$2.21M +$2.32M +165,036 New
SSA
27
Schonfeld Strategic Advisors
New York
$2.18M +$2.29M +162,759 New
NAM
28
Nexpoint Asset Management
Texas
$2.01M +$2.11M +150,025 New
MBAML
29
Marble Bar Asset Management LLP
$1.97M +$2.07M +147,000 New
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
$1.87M +$1.97M +139,973 New
BCL
31
Bracebridge Capital LLC
Massachusetts
$1.86M +$1.96M +139,239 New
Nomura Holdings
32
Nomura Holdings
Japan
$1.84M +$1.93M +137,380 New
Bank of America
33
Bank of America
North Carolina
$1.82M +$1.91M +136,248 New
YCM
34
Yakira Capital Management
Connecticut
$1.69M +$1.78M +126,645 New
CDMG
35
Creek Drive Management Group
California
$1.6M +$1.69M +120,000 New
Charles Schwab
36
Charles Schwab
California
$1.56M +$1.64M +116,598 New
TD Asset Management
37
TD Asset Management
Ontario, Canada
$1.49M +$1.56M +111,200 New
Citadel Advisors
38
Citadel Advisors
Florida
$1.47M +$1.54M +109,936 New
AC
39
Athos Capital
Hong Kong
$1.44M +$1.52M +107,965 New
CM
40
Caption Management
Oklahoma
$1.39M +$1.46M +103,592 New
Northern Trust
41
Northern Trust
Illinois
$1.32M +$1.39M +98,585 New
VFT
42
Vanguard Fiduciary Trust
Pennsylvania
$1.27M +$1.34M +95,128 New
Fidelity International
43
Fidelity International
Bermuda
$1.05M +$1.1M +78,500 New
ECM
44
ExodusPoint Capital Management
New York
$1.04M +$1.09M +77,442 New
Tudor Investment Corp
45
Tudor Investment Corp
Connecticut
$954K +$1M +71,359 New
PAMP
46
Polar Asset Management Partners
Ontario, Canada
$936K +$984K +70,000 New
Neuberger Berman Group
47
Neuberger Berman Group
New York
$926K +$974K +69,294 New
QL
48
Quarry LP
New York
$891K +$936K +66,651 New
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$834K +$876K +62,379 New
ACM
50
ADAR1 Capital Management
Texas
$771K +$811K +57,688 New
1
2
3 4 5

RNA Hedge Fund Activity: Q1 2026 in Review

162 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Atrium Therapeutics (RNA) for Q1 2026, worth a combined $198M.

Buyers outnumbered sellers: 162 funds opened new RNA positions and 0 closed out — a net gain of 162 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $21.8M.

  • 162 institutional investors held Atrium Therapeutics (RNA) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $198M of Atrium Therapeutics stock for Q1 2026.
  • 162 funds opened new Atrium Therapeutics positions in Q1 2026 and 0 closed out, a net change of +162 holders.
  • The largest Atrium Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $21.8M added.

Based on aggregated 13F filings for Q1 2026.